Current Studies

If you are interested in participating in a DVTU study, please contact us to receive notices about current and future research studies.

Dr. Swamy and Dr. Hughes are leading a study to assess the population pharmacokinetics of azithromycin and ertapenem administered as standard of care in pregnant women with failed labor leading to cesarean section.
Dr. Walter is leading the Duke site for a Phase 2 study to assess the safety, reactogenicity, and immunogenicity of an inactivated influenza A/H7N9 virus vaccine administered with or without AS03 adjuvant.  Further information about this study can be found at clinicaltrials.gov.
Dr. Swamy and Dr. Tsalik are leading a study looking at procalcitonin (PCT) levels as a marker for bacterial versus viral lower respiratory tract infections.  This study randomizes subjects with low PCT to azithromycin or placebo.  Further information about this study can be found at clinicaltrials.gov.
Dr. Greenberg and Dr. Walter are leading a multicenter study to assess apnea following vaccination in premature infants receiving their standard of care two-month vaccinations. Furhtur informatiom about this study can be found at clinicaltrials.gov.
Dr. Schmader and Dr. Walter are leading a study to assess the safety and immunogenicity of adjuvanted versus high-dose inactivated flu vaccine in older adults. Further information about the trial can be found at clinicaltrials.gov.
Dr. Walter is leading a study to assess fever in young children after simultaneous vaccination or sequential vaccination with inactivated influenza and PCV13/DTaP vaccines. Further information about the trial can be found at clinicaltrials.gov.
Dr. Schmader is conducting a study to assess the population pharmacokinetics of meropenem and piperacillin-tazobactam administered in adults per clinical care.  This study is looking at drug metabolism across age ranges.
Dr. Walter and Dr. Greenberg are conducting a study to assess the population pharmacokinetics of moxifloxacin administered to children per clinical care.
Dr. Walter is leading the Duke site for a study to assess the safety, reactogenicity, and immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine administered at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants. Further information about the trial can be found at clinicaltrials.gov.
Dr. Walter is leading the Duke site for a study to evaluate shorter duration antibiotic therapy in children diagnosed with Community Acquired Pneumonia (CAP). Subjects will be randomized at day 5 to receive the full course of antibiotic therapy or placebo. Additional information about the study can be found at the link and at clinicaltrials.gov.
Dr. Swamy and Dr. Juel are leading a study to evaluate NTM-1633 in three dose cohorts (A: 0.033 mg/kg, B: 0.165 mg/kg, and C: 0.33 mg/kg). NTM-1633 is a mixture of three monoclonal antibodies designed to treat botulinum neurotoxin BoNT/E poisoning in adults.
Dr. Walter and Dr. Naggie are leading a study to assess the effectiveness of early antifungal treatment (Fluconazole, 400 mg/day) for coccidioidomycosis pneumonia (also referred to as Valley Fever (VF) Pneumonia or acute onset valley fever) vs. placebo in subjects with coccidioidomycosis pneumonia. Recruitment will take place at sites in areas where VF is endemic, including Arizona and California. Further information about the trial can be found at clinicaltrials.gov.
Dr. Swamy is participating in a Phase 3 study to evaluate the safety and immunogenicity of Novavax RSV-F protein nanoparticle vaccine, with aluminum, in healthy pregnant women. This study is international and will be enrolling 8,255 pregnant women. The study will also evaluate the levels of RSV serotype-specific antibodies in infants, and placental transfer from the pregnant women to the infant. Further information about the trial can be found at clinicaltrials.gov.
Dr. Swamy is participating in a pilot study to assess the safety and immunogenicity of sequential vs. simultaneous co-administration of US-licensed tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) adsorbed and inactivated influenza vaccine in 40 pregnant women. Further information can be found at clinicaltrials.gov.

Dr. Walter is leading the Duke site in a study to evaluate the safety of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) in children with asthma of varying levels of severity.  The study is multicenter and will be enrolling 300 children.  Subjects will be randomized to receive either LAIV4 or IIV4.

Dr. Walter is leading a study to assess the feasibility of using clinic-based interventions (Buzzy alone, music alone, or Buzzy and music together) to prevent post-vaccination presyncope in adolescents.The study is single site and enrolling 30 adolescents, 10-17 years of age. More information about the trial can be found at clinicaltrials.gov.